Caliway Biopharmaceuticals Co. L
6919
Clasificación en acciones
#4340
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Precio por acción
$2.29
Capitalización bursátil
$3.56B
Cambio (1 día)
-2.50%
Cambio (1 año)
-57.22%
País
TW
Comercio Caliway Biopharmaceuticals Co. L (6919)
Categoría
Healthcare
Historial del precio de la acción de Caliway Biopharmaceuticals Co. L (6919)
Precio más alto de cierre: $2.44 el 2026-10-01
Precio más bajo de cierre: $0.20 el 2022-12-01
Precio más bajo de cierre: $0.20 el 2022-12-01
Historial del precio de la acción de Caliway Biopharmaceuticals Co. L desde 2022 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $531.67 | 24.68% |
US
|
|
| $237.10 | 783.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $895.07 | 9.94% |
NL
|
|
| $288.17 | 1.24% |
BE
|
